Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study

INTRODUCTION: Despite Tocilizumab is now recognized as a concrete therapeutic option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about factors influencing the response to it in this context. Therefore, the aim of our study was to provide evidence about predictors...

Descripción completa

Detalles Bibliográficos
Autores principales: Masotti, Luca, Landini, Giancarlo, Panigada, Grazia, Grifoni, Elisa, Tarquini, Roberto, Cei, Francesco, Cimolato, Barbara Maria Angela, Vannucchi, Vieri, Di Pietro, Massimo, Piani, Fiorella, Fortini, Alberto, Faraone, Antonio, Nenci, Gabriele, Cipollini, Franco, Blanc, Pierluigi, Lotti, Pamela, Di Natale, Massimo, Risaliti, Filippo, Aquilini, Donatella, Seravalle, Cristiana, Bribani, Andrea, Farsi, Alessandro, Micheletti, Irene, Cioni, Elisa, Pelagalli, Giulia, Mattaliano, Chiara, Pinto, Gabriele, Madonia, Elisa Maria, Sivieri, Irene, Mannini, Marianna, Valoriani, Alice, Brancati, Simona, Rosselli, Matteo, Pavone, Eleonora, Burla, Maria Chiara, Sergi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938681/
https://www.ncbi.nlm.nih.gov/pubmed/35334359
http://dx.doi.org/10.1016/j.intimp.2022.108709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938681/
https://www.ncbi.nlm.nih.gov/pubmed/35334359
http://dx.doi.org/10.1016/j.intimp.2022.108709

Ejemplares similares